The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; GC Pharma; Lilly; Menarini; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Samyang; ST Cube; Takeda
Consulting or Advisory Role - ST Cube
 
Aflah Roohullah
Employment - Sydney Southwest Private Hospital
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus therapeutics; Guardant Health; J INTS BIO; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Charlotte Rose Lemech
No Relationships to Disclose
 
Paul L. de Souza
Stock and Other Ownership Interests - Filamon Pty
Consulting or Advisory Role - Biosceptre International; Harbour BioMed
 
Michael Millward
Consulting or Advisory Role - Amgen; BeiGene; Guardant Health; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda; The Limbic
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); AtriCure (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Dizal Pharma (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genfleet Therapeutics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Lilly (Inst); Maxinovel (Inst); Novartis (Inst); Relay Therapeutics (Inst); Roche (Inst); Takeda (Inst); Therapim (Inst); Turning Point Therapeutics (Inst); Vivace Therapeutics (Inst); Vivace Therapeutics (Inst)
 
Jun Young Choi
Leadership - ABION
Stock and Other Ownership Interests - ABION
Patents, Royalties, Other Intellectual Property - ABION
 
Kyung Eui Park
Employment - ABION
Stock and Other Ownership Interests - ABION
Patents, Royalties, Other Intellectual Property - ABION
 
Na Young Kim
Employment - ABION
Stock and Other Ownership Interests - ABION
Patents, Royalties, Other Intellectual Property - ABION
 
EuiYoung Kim
Employment - ABION
 
Saehyung Lee
Employment - ABION
Patents, Royalties, Other Intellectual Property - ABION
 
YeongMun Kim
Employment - ABION
Stock and Other Ownership Interests - ABION
Patents, Royalties, Other Intellectual Property - ABION
 
YOUNGKEE Shin
Leadership - ABION
Stock and Other Ownership Interests - ABION
Patents, Royalties, Other Intellectual Property - ABION
 
Ji-Youn Han
Honoraria - AstraZeneca; Bristol-Myers Squibb; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda